ClinicalTrials.gg
Not yet recruitingNCT06756126Updated Jan 1, 2025

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

A Phase 2 interventional study of AK120 in Atopic Dermatitis, sponsored by Akeso. Not yet recruiting at 6 sites in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-01.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
173rd of 190
24 · median 164
Started
2024
with 36 others
Phase 2
58 of 206
16 open now
Primary completion
2025-06
later than 12 of 81 live
Registered
134th of 206
by date
Lead sponsor
6 of 206
Akeso

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 173rd largest by planned enrollment of the 190 interventional ones that give a count, is one of 37 that started in 2024, is one of 58 in phase 2, reaches primary completion later than 12 of the 81 other live ones, and was the 134th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis

Read the detailed description

This is a A multicenter, open label, phase II clinical study aimed to evaluate the safety, PK, PD, and preliminary efficacy of AK120 in adolescents with moderate-to-severe AD. The entire study include screening period(week -4 to week 0), treatment and follow-up period(16 weeks). The duration of the study is about 20 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥12 \<18 years old.
  • Weight≥30kg at baseline.
  • AD diagnosed at least half a year before screening.
  • Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Acute onset of AD in 4 weeks prior to enrollment.
  • Undergone or planned surgery during the study period within the 4 weeks prior to enrollment, or unable to fully recover from surgery before enrollment.
  • Previously suffered from vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC).
  • Received systemic traditional Chinese medicine treatment within the 4 weeks before randomization or topical traditional Chinese medicine treatment within 1 week before randomization.
  • Received treatment with other clinical study drugs within 1 month or 5 half-lives before randomization (whichever is longer).
  • Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    AK120 300mg every two weeks (Q2W) subcutaneous injection

    Subjects with heavy weight

    Drug: AK120

  • Experimental
    AK120 300mg every three weeks (Q3W) subcutaneous injection

    Subjects with light weight

    Drug: AK120

Interventions

  • DrugAK120

    AK120 subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events(AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: week -4 to week 16

Secondary outcomes

  1. PK evaluation: maximum plasma concentration (Cmax)

    Assessment of Cmax after AK120 administration.

    Time frame: Baseline till last follow-up visit ( up to day 113)

  2. PK evaluation: time to maximum plasma concentration (Tmax)

    Assessment of Tmax after AK120 administration.

    Time frame: Baseline till last follow-up visit ( up to day 113)

  3. PD evaluation: Thymus and activation regulated chemokine (TARC)/CCL17

    Percentage change in TARC/CCL17 compared to baseline.

    Time frame: Baseline till last follow-up visit ( up to day 113)

  4. Change in Eczema Area and Severity Index (EASI) scores

    Percentage change in EASI scores from baseline.

    Time frame: week 0/2/4/8/12/16

  5. Change in affected Body Surface Area (BSA) scores

    Percentage change in BSA score from baseline.

    Time frame: week 0/2/4/8/12/16

  6. Subjects who achieved 0/1 in the Investigator's Global Assessment (IGA)

    Percentage of subjects who achieved IGA 0/1.

    Time frame: week 0/2/4/8/12/16

  7. Change in Children's Dermatology Life Quality Index (CDLQI) scores

    Percentage change in CDLQI score from baseline.

    Time frame: week 0/2/4/8/12/16

  8. Change in Patient Oriented Eczema Measure (POEM) scores

    Percentage change in POEM score from baseline.

    Time frame: week 0/2/4/8/12/16

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Jun 2025, 6 months later.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 6 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Jan 1, 2025
StartEst.
Dec 30, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06756126
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Dec 30, 2024 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jan 1, 2025

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
86 (0760) 8987 3999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion